EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting Ataxia Telangiectasia-Mutated and Rad3-Related for Anaplastic Thyroid Cancer

Shu-Fu Lin iD, Chuen Hsueh, Wei-Yi Chen, Ting-Chao Chou, Richard J Wong

Cancers · 22.01.2025 · 17 (3) · 359

DOI: 10.3390/cancers17030359 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 22.01.2025. Verfasst von Shu-Fu Lin und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology and Metabolism, Department of Internal Medicine, New Taipei Municipal TuCheng Hospital, New Taipei City 23652, Taiwan. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, New Taipei Municipal TuCheng Hospital (built and operated by Chang Gung Medical Foundation), New Taipei City, Taiwan, National Science and Technology Council of Taiwan, Republic of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Anaplastic thyroid cancer (ATC) is one of the most aggressive human malignancies and has a poor prognosis. Ataxia telangiectasia mutated and Rad3 related (ATR) is a key regulator for the DNA damage response and a potential target to treat cancer.

Methods

We assessed the efficacy of BAY 1895344, an ATR inhibitor, in three ATC cell lines.

Results

BAY 1895344 caused dose–response cytotoxicity in three ATC cell lines. BAY 1895344 induced S-phase and G2-phase arrest, activated caspase-3 activity and induced apoptosis in ATC cells. BAY 1895344 meaningfully retarded the tumor growth of an ATC xenograft model. BAY 1895344 therapy, combined with dabrafenib and trametinib, had synergism in vitro and revealed robust tumor growth suppression in vivo in two xenograft models of ATC harboring mutant BRAFV600E. Furthermore, the combination of BAY 1895344 with lenvatinib was more effective than either agent alone in a xenograft model of ATC.

Conclusions

These results reveal that BAY 1895344 has potential in treating ATC.

Schlagwörter

Stichwörter der Autor:innen

ATRBAY 1895344anaplastic thyroid cancercombination therapykinase inhibitor

Autor:innen und Institutionen

  • Division of Endocrinology and Metabolism, Department of Internal Medicine, New Taipei Municipal TuCheng Hospital, New Taipei City 23652, Taiwan.
  • College of Medicine, Chang Gung University, Taoyuan 33302, Taiwan.
  • Department of Pathology, Chang Gung Memorial Hospital, Taoyuan 33305, Taiwan.
  • Institute of Biochemistry and Molecular Biology, National Yang Ming Chiao Tung University, Taipei 11221, Taiwan.
  • Laboratory of Preclinical Pharmacology Core, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

ORCID-Profile: Shu-Fu Lin

Förderung

  • NCI NIH HHS
  • New Taipei Municipal TuCheng Hospital (built and operated by Chang Gung Medical Foundation), New Taipei City, Taiwan
  • National Science and Technology Council of Taiwan, Republic of China

Zitieren

APA

Lin, S. F., Hsueh, C., Chen, W. Y., Chou, T. C., & Wong, R. J. (2025). Targeting Ataxia Telangiectasia-Mutated and Rad3-Related for Anaplastic Thyroid Cancer. Cancers, 17(3), 359. https://doi.org/10.3390/cancers17030359

Vancouver

Lin SF, Hsueh C, Chen WY, Chou TC, Wong RJ. Targeting Ataxia Telangiectasia-Mutated and Rad3-Related for Anaplastic Thyroid Cancer. Cancers. 2025;17(3):359. doi:10.3390/cancers17030359

BibTeX
@article{Lin2025,
  author = {Lin, Shu-Fu and Hsueh, Chuen and Chen, Wei-Yi and Chou, Ting-Chao and Wong, Richard J},
  title = {Targeting Ataxia Telangiectasia-Mutated and Rad3-Related for Anaplastic Thyroid Cancer},
  journal = {Cancers},
  year = {2025},
  volume = {17},
  number = {3},
  pages = {359},
  doi = {10.3390/cancers17030359}
}
Kostenlos starten →